Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer

Autor: Jiahong Liang, Qiaodong Xu, Xianyu Hu, Songgang Gu, Qing Wang, Jiang Yan
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Value (ethics)
Oncology
Immunology & Inflammation
medicine.disease_cause
Biochemistry
0302 clinical medicine
Risk Factors
Databases
Genetic
Tumor Microenvironment
Immune Checkpoint Inhibitors
Diagnostics & Biomarkers
Research Articles
Cancer
B-Lymphocytes
Genomics
Prognosis
Gene Expression Regulation
Neoplastic
medicine.anatomical_structure
030220 oncology & carcinogenesis
Cell Cycle
Growth & Proliferation
cell cycle
immunotherapy
Stomach Adenocarcinoma
Signal Transduction
medicine.medical_specialty
Poor prognosis
Antimetabolites
Antineoplastic
Clinical Decision-Making
Biophysics
Adenocarcinoma
Risk Assessment
03 medical and health sciences
Lymphocytes
Tumor-Infiltrating
Predictive Value of Tests
Stomach Neoplasms
Internal medicine
Cell Line
Tumor
medicine
Overall survival
Biomarkers
Tumor
Humans
Molecular Biology
B cell
business.industry
Proportional hazards model
gastric cancer
Cell Biology
medicine.disease
Early B-cell factors
Histone Deacetylase Inhibitors
030104 developmental biology
immune
Carcinogenesis
business
Zdroj: Bioscience Reports
ISSN: 1573-4935
0144-8463
Popis: Gastric cancer (GC) is a heavy health burden around the world, which is the fifth most frequent tumor and leads to the third most common cancer-related deaths. It is urgent to identify prognostic markers as the guideline for personalized treatment and follow-up. We accessed the prognostic value of Early B-cell factors (EBFs) in GC. A total of 415 GC tissues and 34 normal tissues from The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) cohort, 616 external patients from {"type":"entrez-geo","attrs":{"text":"GSE15459","term_id":"15459"}}GSE15459, {"type":"entrez-geo","attrs":{"text":"GSE22377","term_id":"22377"}}GSE22377, {"type":"entrez-geo","attrs":{"text":"GSE51105","term_id":"51105"}}GSE51105, {"type":"entrez-geo","attrs":{"text":"GSE62245","term_id":"62245"}}GSE62245 were enrolled for analysis. Univariate and multivariate Cox regression analyses were employed to evaluate the sole and integrative prognostic value of EBFs, respectively. Genetic alterations, DNA methylation of EBFs were also evaluated, as well as the involved signaling pathways. We revealed that increased EBFs associated with the poor prognosis of GC patients, the prognostic model was established in TCGA-STAD cohort, and validated in Gene Expression Omnibus (GEO) cohorts, with effectiveness in both HER2 positive and negative patients. DNA methylation was involved in the impact on prognosis. Cell cycle, immune-associated, and MAPK pathways were influenced by EBFs. Anti-CTLA4 immunotherapy is more suitable for EBFs determining high-risk groups, but not anti-PD-1/PD-L1 therapy. 5-Fluorouracil, methotrexate, vorinostat are suitable to inhibit the function of EBFs. Our new findings provide novel insight into the prediction of prognosis and clinical treatment of GC patients based on EBFs.
Databáze: OpenAIRE
Externí odkaz: